Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acquired | Acquired

Total Raised


About Heartscape Technologies

Heartscape Technologies offers an FDA approved medical device, per the company, for diagnosis of heart attacks and ischemia in the emergency room setting.

Heartscape Technologies Headquarters Location

9160 Rumsey Road Suite B-8

Columbia, Maryland, 21045,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Heartscape Technologies Patents

Heartscape Technologies has filed 7 patents.

patents chart

Application Date

Grant Date


Related Topics





Application Date


Grant Date



Related Topics



  • Where is Heartscape Technologies's headquarters?

    Heartscape Technologies's headquarters is located at 9160 Rumsey Road, Columbia.

  • What is Heartscape Technologies's latest funding round?

    Heartscape Technologies's latest funding round is Acquired.

  • How much did Heartscape Technologies raise?

    Heartscape Technologies raised a total of $21.4M.

  • Who are the investors of Heartscape Technologies?

    Investors of Heartscape Technologies include Roper Technologies, Radius Ventures, Delta Private Equity Partners, Investor Growth Capital and Scottish Equity Partners.

  • Who are Heartscape Technologies's competitors?

    Competitors of Heartscape Technologies include JenaValve, Itamar Medical, SynCardia Systems, Soteira, Concentric Medical and 11 more.

You May Also Like

NeoChord Logo

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

JenaValve Logo

JenaValve develops, manufactures, and markets transcatheter aortic valve implantation systems (TAVI) to treat patients suffering from aortic valve disease. The company's transapical aortic valve system is CE-marked and currently marketed in Europe and other markets worldwide. The company was founded in 2006 and is based in Irvine, California.

CoAptus Medical

CoAptus is developing a catheter device to seal up heart defects.

FocalCool Logo

FocalCool is a medical device company. The company's goal is to develop technology that aims to reduce tissue damage from heart attacks and strokes. Using a special catheter system the company can apply rapid localized cooling to internal organs. The FocalCool team is made up of a Rowan University engineering professor, two engineers (one is a Rowan engineering graduate), and several Rowan engineering students.


Cardiola have designed a patented device, the m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient's home.

Chase Medical

Chase Medical is developing medical technology for treating congestive heart failure. Chase Medical is developing a device called the Mannequin which aims to help the heart maintain its shape while going through reconstruction of the left ventricle.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.